Someone tell me why this stock (IPIX) is basically sitting stagnant with all its possibilities on the shelf? I know it has bad management, according to posters, but I see worse biotech stocks, with less on the shelf, outperforming IPIX by leaps & bounds.
"In the need of reinforcing the drug repositioning strategy and developing specific SARS-CoV-2 treatment, recently, three main groups of scientists discovered that a new antibacterial drug, named brilacidin, provides attractive benefits against SARS-CoV-2, and specifically without major side effects. This previous findings were confirmed by Xu, et al. [2], who further, specified that the protective effect of brilacidin is more likely to be preventive than curative, as brilacidin has no inhibition/protective effect after SARS-CoV-2-cell attachment, but only can inhibit SARS-CoV-2 entry into cells. Furthermore, while Xu, et al. [2] demonstrated the effectiveness of brilacidin against SARS-CoV-2 and its derivative variants including P.1 and B.1.1.7 strains, Hu, et al. [3] discovered that brilacidin protective activity has a broader spectrum to other sarbecoviruses, including OC43, 229E, and NL63 strains. Highlights 1. Brilacidin protects cells from SARS-Co-2 infection, at low dose. 2. Brilacidin has a broad-spectrum antiviral activity against multiple Human Coronaviruses (HCoVs) including SARS-CoV-2 and its derivatives, HCoV- 229E, HCoV-OC43, and HCoV-NL63. 3. Brilacidin has a dual antiviral mechanism of action, including virucidal activity and binding to coronavirus attachment factor HSPGs on the host cell surface https://www.jelsciences.com/articles/jbres1504.pdf
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.